DK2905335T3 - Anti-humant dlk-1 antistof med anti-tumoraktivitet in vivo - Google Patents
Anti-humant dlk-1 antistof med anti-tumoraktivitet in vivo Download PDFInfo
- Publication number
- DK2905335T3 DK2905335T3 DK13843070.7T DK13843070T DK2905335T3 DK 2905335 T3 DK2905335 T3 DK 2905335T3 DK 13843070 T DK13843070 T DK 13843070T DK 2905335 T3 DK2905335 T3 DK 2905335T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- val
- thr
- gly
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Antistof mod humant Dlk-1, hvor aminosyresekvensen ifølge det variable område af tungkæden omfatter aminosyresekvensen ifølge en hvilken som helst af SEQ ID NO: 35, 40, 69, 73, 77, 81, 85 og 89, og aminosyresekvensen ifølge det variable område af letkæden omfatter aminosyresekvensen ifølge SEQ ID NO: 45.
2. Antistof ifølge krav 1, der: (a) har en anti-tumoraktivitet in vivo\ og/eller (b) binder til mindst en del af et område, der omfatter aminosyrer ved positionerne 24 til 91 i aminosyresekvensen ifølge human Dlk-1 ifølge SEQ ID NO: 2.
3. Antistof ifølge krav 1 eller 2, der er et humaniseret antistof eller et monoklonalt antistof.
4. Kompleks, der omfatter antistoffet ifølge et hvilket som helst af kravene 1 til 3 og en forbindelse med en antitumoraktivitet og/eller en celledræbende aktivitet.
5. Farmaceutisk sammensætning, der omfatter mindst ét af antistof ifølge et hvilket som helst af kravene 1 til 3 og kompleks ifølge krav 6.
6. Antistof ifølge et hvilket som helst af kravene 1 til 3, kompleks ifølge krav 4 eller sammensætning ifølge krav 5 til anvendelse i en fremgangsmåde til behandling eller diagnose af en tumor.
7. Antistof ifølge et hvilket som helst af kravene 1 til 3, kompleks ifølge krav 4 eller sammensætning ifølge krav 5 til anvendelse i en fremgangsmåde til induktion af apoptose i tumorceller.
8. Antistof, sammensætning eller kompleks til anvendelse ifølge krav 6 eller 7, hvor tumoren er mindst én af human coloncancer, human brystcancer, human levercancer, human pancreascancer, human småcellet lungecancer og humant neuroblastom.
9. Tumorterapeutisk middel, der omfatter mindst ét af antistoffet ifølge et hvilket som helst af kravene 1 til 3 og komplekset ifølge krav 4.
10. Sammensætning ifølge krav 5 eller terapeutisk middel ifølge krav 9, der ikke forårsager vægtreduktion som en bivirkning.
11. Middel egnet til at inducere apoptose i tumorceller, der omfatter mindst ét af antistof ifølge et hvilket som helst af kravene 1 til 3 og komplekset ifølge krav 4.
12. Kit egnet til behandling, diagnosticering eller detektering af en tumor eller til induktion af apoptose i tumorceller, der omfatter mindst ét af antistof ifølge et hvilket som helst af kravene 1 til 3 og kompleks ifølge krav 4.
13. Antistof ifølge krav 2, kompleks ifølge krav 4, sammensætning ifølge krav 10, terapeutisk middel ifølge krav 9 eller 10, apoptoseinducerende middel ifølge krav 11 eller kit ifølge krav 12, hvor tumoren er mindst én af human coloncancer, human brystcancer, human levercancer, human pancreascancer, human småcellet lungecancer og humant neuroblastom.
14. Fremgangsmåde til detektering af en tumor, der omfatter: at gøre det muligt for mindst ét af antistof ifølge et hvilket som helst af kravene 1 til 3 og kompleks ifølge krav 4 at blive omsat med en prøve fra en levende krop; og detektering af et eller flere signaler fra det omsatte antistof og/eller antistoffragmentet.
15. Fremgangsmåde ifølge krav 14, hvor tumoren er mindst én af human coloncancer, human brystcancer, human levercancer, human pancreascancer, human småcellet lungecancer og humant neuroblastom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709282P | 2012-10-03 | 2012-10-03 | |
| PCT/JP2013/077540 WO2014054820A1 (ja) | 2012-10-03 | 2013-10-03 | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2905335T3 true DK2905335T3 (da) | 2018-03-12 |
Family
ID=50435137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13843070.7T DK2905335T3 (da) | 2012-10-03 | 2013-10-03 | Anti-humant dlk-1 antistof med anti-tumoraktivitet in vivo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9303086B2 (da) |
| EP (1) | EP2905335B1 (da) |
| JP (1) | JP6280040B2 (da) |
| KR (1) | KR102149565B1 (da) |
| CN (1) | CN104704119B (da) |
| AU (1) | AU2013325443B2 (da) |
| CA (1) | CA2886772C (da) |
| CY (1) | CY1120063T1 (da) |
| DK (1) | DK2905335T3 (da) |
| ES (1) | ES2665341T3 (da) |
| HR (1) | HRP20180685T1 (da) |
| HU (1) | HUE037274T2 (da) |
| LT (1) | LT2905335T (da) |
| NO (1) | NO2972360T3 (da) |
| PL (1) | PL2905335T3 (da) |
| PT (1) | PT2905335T (da) |
| RS (1) | RS57120B1 (da) |
| SI (1) | SI2905335T1 (da) |
| WO (1) | WO2014054820A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101619862B1 (ko) * | 2014-09-30 | 2016-05-12 | 주식회사 녹십자 | 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법 |
| CA3047686C (en) | 2017-02-08 | 2020-07-07 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| KR102125032B1 (ko) | 2017-09-08 | 2020-06-19 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
| CN113660954A (zh) * | 2019-04-01 | 2021-11-16 | 凯奥目生物科学株式会社 | 癌症治疗用药物 |
| KR20230083296A (ko) * | 2020-10-05 | 2023-06-09 | 치오메 바이오사이언스 가부시키가이샤 | 암 치료용 의약 |
| IL308169A (en) | 2021-05-10 | 2024-01-01 | Chiome Bioscience Inc | Purification method of an antibody compound |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69229477T2 (de) * | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69329037T2 (de) | 1992-12-11 | 2001-03-22 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Delta ähnliches gen welches in neuroendokrinen tumoren exprimiert wird |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP2001269174A (ja) | 2000-03-24 | 2001-10-02 | Kirin Brewery Co Ltd | 骨髄異形成症候群（ｍｄｓ）の検出方法及びｍｄｓの治療剤 |
| US20030185815A1 (en) | 2001-04-03 | 2003-10-02 | Muralidhara Padigaru | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| WO2003018779A1 (en) | 2001-08-24 | 2003-03-06 | Nsgene A/S | Isolation of cells from neural cell populations using antibodies to fa1/dlk1 |
| EP2287199B1 (en) * | 2002-03-13 | 2017-08-02 | Biogen MA Inc. | Anti-alpha V beta 6 antibodies |
| US20050221392A1 (en) | 2002-03-21 | 2005-10-06 | Charlotte Harken Jensen | Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1 |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| ES2345493T3 (es) | 2003-11-28 | 2010-09-24 | Kanagawa Academy Of Science And Technology | Metodo de deteccion de cancer de higado, diagnostico de cancer de higado y remedio para el cancer. |
| CN103073641B (zh) | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| EP2275537B1 (en) * | 2008-03-17 | 2014-12-24 | Livtech Inc. | Anti-human dlk-1 antibody having anti-tumor activity in vivo |
| US8975376B2 (en) * | 2010-02-23 | 2015-03-10 | Sanofi | Anti-alpha2 integrin antibodies and their uses |
| TR201900368T4 (tr) * | 2010-05-04 | 2019-02-21 | Five Prime Therapeutics Inc | Csf1r'ye bağlanan antikorlar. |
-
2013
- 2013-10-03 US US14/045,326 patent/US9303086B2/en active Active
- 2013-10-03 PT PT138430707T patent/PT2905335T/pt unknown
- 2013-10-03 EP EP13843070.7A patent/EP2905335B1/en active Active
- 2013-10-03 DK DK13843070.7T patent/DK2905335T3/da active
- 2013-10-03 LT LTEP13843070.7T patent/LT2905335T/lt unknown
- 2013-10-03 AU AU2013325443A patent/AU2013325443B2/en active Active
- 2013-10-03 CA CA2886772A patent/CA2886772C/en active Active
- 2013-10-03 ES ES13843070.7T patent/ES2665341T3/es active Active
- 2013-10-03 RS RS20180437A patent/RS57120B1/sr unknown
- 2013-10-03 WO PCT/JP2013/077540 patent/WO2014054820A1/ja active Application Filing
- 2013-10-03 CN CN201380051895.5A patent/CN104704119B/zh active Active
- 2013-10-03 PL PL13843070T patent/PL2905335T3/pl unknown
- 2013-10-03 HU HUE13843070A patent/HUE037274T2/hu unknown
- 2013-10-03 JP JP2014539861A patent/JP6280040B2/ja active Active
- 2013-10-03 SI SI201330954T patent/SI2905335T1/en unknown
- 2013-10-03 KR KR1020157009420A patent/KR102149565B1/ko active IP Right Grant
-
2014
- 2014-03-14 NO NO14721647A patent/NO2972360T3/no unknown
-
2018
- 2018-03-23 CY CY20181100334T patent/CY1120063T1/el unknown
- 2018-04-30 HR HRP20180685TT patent/HRP20180685T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013325443A1 (en) | 2015-04-09 |
| CN104704119B (zh) | 2017-09-05 |
| CA2886772A1 (en) | 2014-04-10 |
| EP2905335A4 (en) | 2016-05-18 |
| HRP20180685T1 (hr) | 2018-06-01 |
| ES2665341T3 (es) | 2018-04-25 |
| US9303086B2 (en) | 2016-04-05 |
| EP2905335A1 (en) | 2015-08-12 |
| JP6280040B2 (ja) | 2018-02-14 |
| LT2905335T (lt) | 2018-04-10 |
| PT2905335T (pt) | 2018-03-12 |
| SI2905335T1 (en) | 2018-04-30 |
| US20140193432A1 (en) | 2014-07-10 |
| CA2886772C (en) | 2021-01-12 |
| CN104704119A (zh) | 2015-06-10 |
| HUE037274T2 (hu) | 2018-08-28 |
| EP2905335B1 (en) | 2018-01-31 |
| CY1120063T1 (el) | 2018-12-12 |
| NO2972360T3 (da) | 2018-08-04 |
| JPWO2014054820A1 (ja) | 2016-08-25 |
| AU2013325443B2 (en) | 2019-01-31 |
| WO2014054820A1 (ja) | 2014-04-10 |
| KR102149565B1 (ko) | 2020-08-28 |
| RS57120B1 (sr) | 2018-06-29 |
| KR20150060761A (ko) | 2015-06-03 |
| PL2905335T3 (pl) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6847037B2 (ja) | 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用 | |
| AU2007318483B2 (en) | Anti-human Dlk-1 antibody showing anti-tumor activity in vivo | |
| JP6755866B2 (ja) | Ｃｄ７３特異的結合分子及びその使用 | |
| CA2798778C (en) | Anti-human trop-2 antibody having anti-tumor activity in vivo | |
| US8017118B2 (en) | Anti-hDlk-1 antibody having an antitumor activity in vivo | |
| JP2022119907A (ja) | 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法 | |
| DK2905335T3 (da) | Anti-humant dlk-1 antistof med anti-tumoraktivitet in vivo | |
| CN108350505A (zh) | 用于测定icos表达的基因标志 | |
| CA3027417A1 (en) | Anti-human trop-2 antibody having an antitumor activity in vivo | |
| TW202402805A (zh) | 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法 |